immunogen

Metastasized breast cancer now has a new therapy on the market, though it remains to be seen whether noticeably dangerous side effects may prevent widespread use. Trastuzumab emtansine (T-DM1) or Kadcyla, produced by Immunogen [Nasdaq: IMGN], is a treatment that targets the HER2 protein.